低温等离子体通过 VEGF/VEGFR2/RAS/ERK 轴抑制肺癌细胞生长。
Low Temperature Plasma Suppresses Lung Cancer Cells Growth via VEGF/VEGFR2/RAS/ERK Axis.
机构信息
Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health & Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei 230031, China.
Hefei Cancer Hospital, Chinese Academy of Sciences, Hefei 230031, China.
出版信息
Molecules. 2022 Sep 13;27(18):5934. doi: 10.3390/molecules27185934.
Low temperature plasma (LTP) is a promising cancer therapy in clinical practice. In this study, dielectric barrier discharge plasma with helium gas was used to generate LTP. Significant increases in extracellular and intracellular reactive species were found in lung cancer cells (CALU-1 and SPC-A1) after LTP treatments. Cells viability and apoptosis assays demonstrated that LTP inhibited cells viability and induced cells death, respectively. Moreover, Western blotting revealed that the growth of CALU-1 cells was suppressed by LTP via the VEGF/VEGFR2/RAS/ERK axis for the first time. The results showed that LTP-induced ROS and RNS could inhibit the growth of lung cancer cells via VEGF/VEGFR2/RAS/ERK axis. These findings advance our understanding of the inhibitory mechanism of LTP on lung cancer and will facilitate its clinical application.
低温等离子体（LTP）是一种有前途的癌症治疗方法，已在临床实践中得到应用。在这项研究中，使用氦气介质阻挡放电等离子体产生 LTP。在 LTP 处理后，肺癌细胞（CALU-1 和 SPC-A1）中外源和内源活性物质显著增加。细胞活力和凋亡检测表明，LTP 分别抑制细胞活力并诱导细胞死亡。此外，Western blot 揭示，LTP 通过 VEGF/VEGFR2/RAS/ERK 轴首次抑制 CALU-1 细胞的生长。结果表明，LTP 诱导的 ROS 和 RNS 可以通过 VEGF/VEGFR2/RAS/ERK 轴抑制肺癌细胞的生长。这些发现加深了我们对 LTP 抑制肺癌的抑制机制的理解，并将促进其临床应用。
Zotero 插件